DURABILITY OF RESPONSE WITH SELPERCATINIB IN PATIENTS WITH RET-ACTIVATED THYROID CANCER: LONG-TERM SAFETY AND EFFICACY FROM LIBRETTO-001.

OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY IN OLDER PATIENTS WITH STAGE III COLON CANCER: AN ACCENT/IDEA POOLED ANALYSIS OF 12 TRIALS.

ADJUVANT TRASTUZUMAB EMTANSINE VERSUS PACLITAXEL PLUS TRASTUZUMAB FOR STAGE I HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER: 5-YEAR RESULTS AND CORRELATIVE ANALYSES FROM ATEMPT